Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, announces an affiliate has acquired Whitecap Biosciences, LLC, which is currently developing two innovative therapies for potential use in glaucoma and geographic atrophy (GA). The acquisition strengthens Bausch + Lomb’s expanding clinical-stage pipeline. Whitecap Biosciences was founded in 2015 to develop novel therapies for ophthalmic diseases with a focus on glaucoma, GA and other serious eye diseases. The company successfully completed Phase 2 clinical trials for WB007, a highly potent alpha-2 adrenergic agonist, in glaucoma.
Read the full article: Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences //
Source: https://www.businesswire.com/news/home/20250113447944/en/Bausch-Lomb-Bolsters-Pipeline-with-Acquisition-of-Whitecap-Biosciences